CommentImmunotherapy for small-cell lung cancer
References (8)
- et al.
Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC)
Eur J Cancer
(2015) - et al.
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer
J Clin Oncol
(2006) - et al.
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Lancet Oncol
(2016) - et al.
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
N Engl J Med
(2015)
There are more references available in the full text version of this article.
Cited by (6)
m<sup>6</sup>A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression
2018, Biochemical and Biophysical Research CommunicationsCitation Excerpt :Within NSCLC, two major subtypes are lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), which account for 50–60% and 30% of cases, respectively. In the past decade, emerging new targeted medicines have remarkably improved the outcome of LUAD patients, whereas the targeted therapies for LUSC are limited [2,3]. Therefore, a better understanding of the molecular mechanism underlying LUSC progression is needed to develop effective therapies.
Comparing strategy of immune checkpoint inhibitors plus chemotherapy with chemotherapy alone for small cell lung cancer: a meta-analysis based on six RCTs incorporating 2800 participants
2022, Journal of Cancer Research and Clinical OncologyArtificial intelligence tools for refining lung cancer screening
2020, Journal of Clinical MedicineThe efficiency and safety of immune checkpoint inhibitors in the treatment of small cell lung cancer: A meta-analysis
2020, Annals of Palliative MedicineA Curated Target Gene Pool Assisting Early Disease Prediction and Patient-Specific Treatment for Small Cell Lung Cancer
2018, Journal of Computational BiologyOngoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China Ahmed Tarhini; Timothy Burns; Rahul Parikh; Guarvel Goel; Annie im
2017, Journal of Hematology and Oncology
© 2016 Elsevier Ltd. All rights reserved.